GlaxoSmithKline Plc said on Thursday its shingles vaccine had been approved for use in China in adults aged 50 and above. The company said the vaccine will be introduced in phases in China, starting in 2020, to ensure reliable supply to all countries, where it has been launched. Shingrix, which has already been approved for use in the European Union, the United States, Canada, Japan and Australia, brought in 357 million pounds ($452.03 million) in the latest quarter.
